Trends and predictors of changes in pulmonary function after treatment for pulmonary tuberculosis

被引:46
作者
Chung, Kuei-Pin [1 ,2 ]
Chen, Jung-Yueh [3 ]
Lee, Chih-Hsin [4 ]
Wu, Huey-Dong [2 ,5 ]
Wang, Jann-Yuan [2 ,5 ]
Lee, Li-Na [1 ,2 ]
Yu, Chong-Jen [2 ,5 ]
Yang, Pan-Chyr [2 ,5 ]
机构
[1] Natl Taiwan Univ Hosp, Dept Lab Med, Taipei, Taiwan
[2] Natl Taiwan Univ Hosp, Coll Med, Taipei, Taiwan
[3] E Da Hosp, Dept Internal Med, Kaohsiung, Taiwan
[4] Buddhist Tzu Chi Gen Hosp, Dept Internal Med, Taipei Branch, Taipei, Taiwan
[5] Natl Taiwan Univ Hosp, Dept Internal Med, Taipei 100, Taiwan
关键词
completion of treatment; disease extent; pulmonary function; pulmonary tuberculosis; LUNG-FUNCTION; RESPIRATORY FUNCTION; IMPAIRMENT; SMOKING; DISEASE; ASSOCIATION; OBSTRUCTION; VOLUME;
D O I
10.1590/S1807-59322011000400005
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
OBJECTIVES: The present study aimed to investigate the trends in changes in pulmonary function and the risk factors for pulmonary function deterioration in patients with pulmonary tuberculosis after completing treatment. INTRODUCTION: Patients usually have pulmonary function abnormalities after completing treatment for pulmonary tuberculosis. The time course for changes in pulmonary function and the risk factors for deterioration have not been well studied. METHODS: A total of 115 patients with 162 pulmonary function results were analyzed. We retrieved demographic and clinical data, radiographic scores, bacteriological data, and pulmonary function data. A generalized additive model with a locally weighted scatterplot smoothing technique was used to evaluate the trends in changes in pulmonary function. A generalized estimating equation model was used to determine the risk factors associated with deterioration of pulmonary function. RESULTS: The median interval between the end of anti-tuberculosis treatment and the pulmonary function test was 16 months (range: 0 to 112 months). The nadir of pulmonary function occurred approximately 18 months after the completion of the treatment. The risk factors associated with pulmonary function deterioration included smear-positive disease, extensive pulmonary involvement prior to anti-tuberculosis treatment, prolonged anti-tuberculosis treatment, and reduced radiographic improvement after treatment. CONCLUSIONS: After the completion of anti-tuberculosis TB treatment, several risk factors predicted pulmonary function deterioration. For patients with significant respiratory symptoms and multiple risk factors, the pulmonary function test should be followed up to monitor the progression of functional impairment, especially within the first 18 months after the completion of anti-tuberculosis treatment.
引用
收藏
页码:549 / 556
页数:8
相关论文
共 34 条
  • [1] ANNO H, 1955, AM REV TUBERC PULM, V71, P333
  • [2] Pivotal clinical dilemmas in collagen vascular diseases associated with interstitial lung involvement
    Antoniou, K. M.
    Margaritopoulos, G.
    Economidou, F.
    Siafakas, N. M.
    [J]. EUROPEAN RESPIRATORY JOURNAL, 2009, 33 (04) : 882 - 896
  • [3] SOX2 is an amplified lineage-survival oncogene in lung and esophageal squamous cell carcinomas
    Bass, Adam J.
    Watanabe, Hideo
    Mermel, Craig H.
    Yu, Soyoung
    Perner, Sven
    Verhaak, Roel G.
    Kim, So Young
    Wardwell, Leslie
    Tamayo, Pablo
    Gat-Viks, Irit
    Ramos, Alex H.
    Woo, Michele S.
    Weir, Barbara A.
    Getz, Gad
    Beroukhim, Rameen
    O'Kelly, Michael
    Dutt, Amit
    Rozenblatt-Rosen, Orit
    Dziunycz, Piotr
    Komisarof, Justin
    Chirieac, Lucian R.
    LaFargue, Christopher J.
    Scheble, Veit
    Wilbertz, Theresia
    Ma, Changqing
    Rao, Shilpa
    Nakagawa, Hiroshi
    Stairs, Douglas B.
    Lin, Lin
    Giordano, Thomas J.
    Wagner, Patrick
    Minna, John D.
    Gazdar, Adi F.
    Zhu, Chang Qi
    Brose, Marcia S.
    Cecconello, Ivan
    Ribeiro, Ulysses, Jr.
    Marie, Suely K.
    Dahl, Olav
    Shivdasani, Ramesh A.
    Tsao, Ming-Sound
    Rubin, Mark A.
    Wong, Kwok K.
    Regev, Aviv
    Hahn, William C.
    Beer, David G.
    Rustgi, Anil K.
    Meyerson, Matthew
    [J]. NATURE GENETICS, 2009, 41 (11) : 1238 - U105
  • [4] BIRATH G, 1966, SCAND J RESPIR DIS, V47, P27
  • [5] CANETTI G, 1965, AM REV RESPIR DIS, V92, P687
  • [6] SIGNIFICANCE OF BRONCHIECTASIS ASSOCIATED WITH PULMONARY TUBERCULOSIS
    CURTIS, JK
    [J]. AMERICAN JOURNAL OF MEDICINE, 1957, 22 (06) : 894 - 903
  • [7] Smoking and tuberculosis: the epidemiological association and immunopathogenesis
    Davies, PDO
    Yew, WW
    Ganguly, D
    Davidow, AL
    Reichman, LB
    Dheda, K
    Rook, GA
    [J]. TRANSACTIONS OF THE ROYAL SOCIETY OF TROPICAL MEDICINE AND HYGIENE, 2006, 100 (04) : 291 - 298
  • [8] Lung remodeling in pulmonary tuberculosis
    Dheda, K
    Booth, H
    Huggett, JF
    Johnson, MA
    Zumla, A
    Rook, GAW
    [J]. JOURNAL OF INFECTIOUS DISEASES, 2005, 192 (07) : 1201 - 1210
  • [9] Diagnostic standards and classification of tuberculosis in adults and children
    Dunlap, NE
    Bass, J
    Fujiwara, P
    Hopewell, P
    Horsburgh, CR
    Salfinger, M
    Simone, PM
    [J]. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2000, 161 (04) : 1376 - 1395
  • [10] GAENSLER EA, 1959, AM REV RESPIR DIS, V80, P185